GENEVA (Reuters) - The GAVI vaccine alliance on Tuesday welcomed Astrazeneca's interim data on efficiency of its COVID-19 vaccine, calling it "positive news for the COVAX vision of equitable access" for vulnerable groups worldwide.
Hundreds of millions of doses of the candidate vaccine have been secured on behalf of the COVAX facility, per agreements, the Geneva-based GAVI alliance that leads the initiative along with the World Health Organization (WHO) said in a statement.
Already a subscriber? Log in.
Subscribe to win RM50 Touch 'n Go e-Voucher! More Info
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!